Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulants.

Lori-Ann Linkins1, Jeffrey I Weitz

  • 1Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada.

Seminars in Thrombosis and Hemostasis
|January 14, 2004
PubMed
Summary
This summary is machine-generated.

New anticoagulants are being developed to overcome limitations of current therapies like heparin and warfarin for thromboembolism. This review covers targets, agents in clinical trials, and future opportunities for novel anticoagulant drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Poly(sulfobetaine-<i>co</i>-oligoethylene Glycol Methyl Ether Methacrylate) Copolymers with Improved Anti-Fouling and Anti-Coagulant Properties.

Biomacromolecules·2026
Same author

A novel biosensor for measuring plasmin activity.

Research and practice in thrombosis and haemostasis·2026
Same author

From Rapid Reviews to Rapid Living Evidence Synthesis: Lessons From COVID-19 Vaccine Effectiveness Reviews for Canadian Public Health Decision-Making.

Campbell systematic reviews·2026
Same author

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Blood·2026
Same author

Long-Term Hydrophilic, Anti-Clotting, and Anti-Fibrotic Dynamic Covalent Silicone-Based Biomaterials.

Advanced healthcare materials·2026

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiovascular Medicine

Background:

  • Heparin and warfarin, traditional anticoagulants, possess significant limitations.
  • These limitations necessitate the development of novel anticoagulant therapies.
  • Venous and arterial thromboembolism remain significant clinical challenges.

Purpose of the Study:

  • To review the mechanisms of venous and arterial thrombogenesis.
  • To discuss the complex regulation of the coagulation cascade.
  • To identify molecular targets and agents in development for novel anticoagulation.

Main Methods:

  • Literature review of thrombogenesis and coagulation.
  • Identification and description of molecular targets for new anticoagulants.

Related Experiment Videos

  • Analysis of agents in advanced clinical testing phases.
  • Clinical perspective on the future of anticoagulant drug development.

    • Main Results:

    • Several novel anticoagulant agents targeting specific molecular pathways are under investigation.
    • A few agents have progressed to Phase II or higher clinical trials.
    • Understanding thrombogenesis and coagulation regulation is key to developing effective anticoagulants.

    Conclusions:

    • Novel anticoagulant drugs offer potential to overcome limitations of current therapies.
    • Targeted molecular approaches are advancing the field of anticoagulation.
    • Further clinical evaluation is crucial to realize the therapeutic potential of new anticoagulant agents.